

Saturday 9 th October 2021 All times: CET (Central European Time)			
Time	Session		
13.00-13:05	Welcome Address Silke Gillissen and Aurelius Omlin on behalf of APCCC		
13.05 – 15.00 Session 1	Management of newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC)	Chairs: Betrand Tombal and Nick James	Duration
	What is the evidence for “triplet therapy” (ADT + radiation of the primary + additional systemic therapy)?	Karim Fizazi	12 min
	What is the evidence for “triplet therapy” (ADT + docetaxel + additional systemic therapy)?	Ian Davis	12 min
	Do different subgroup of patients need different treatments?	Chris Sweeney	12 min
	What can meta-analyses, network meta-analyses and subgroup analyses tell us about treatment options: Pearls and pitfalls	Claire Vale	12 min
	Are there still patients where treatment with ADT alone is appropriate?	Rob Jones	10 min
	Can molecular markers inform treatment decision in mHSPC?	Himisha Beltran	10 min
14.15 – 14.30	Discussion		
14.30 – 14.50	Vote consensus questions		
14:50 - 15.00	Break		
15.00 – 17.00 Session 2	PSMA in diagnostics and therapy	Chairs: Alberto Bossi, Neal Shore	Duration
	PSMA – background	Derya Tilki	10 min
	PSMA PET: Really the best modality for staging to improve clinical outcomes?	Piet Ost	12 min
	PSMA –based imaging: Navigating the pitfalls of the different tracers	Stefano Fanti	12 min
	Do we need the second PET (FDG) for patient selection? (including SUV for selection of PSMA therapy)	Michael Hofman	10 min
	Best use of Lutetium-PSMA and where to put it in sequencing therapies including treatment monitoring	Charles Ryan	12 min
	Novel PSMA targeted agents (BITE’s, cellular therapies, actinium, thorium...)	Eleni Efstathiou	10 min
16.15 – 16.30	Discussion		
16.30 – 16.50	Vote consensus questions		
16.50 – 17.00	Break		
17.00 – 19.00 Session 3	PARP inhibitors and beyond: Molecular characterisation of tissue and blood	Chairs: Nicolas Mottet, Matthew Smith	Duration
	Who needs germline testing and what should be tested?	Dana Rathkopf	12 min
	Somatic testing – When and what? (including mismatch repair evaluation)	Maha Hussain	12 min
	Tumor molecular testing – tissue vs liquid biopsy	Andrew Armstrong	12 min

	DNA repair defect aberrations – What are the differences between them and what is the impact on patient management?	Johann De Bono	15 min
	Novel and not so novel agents and where to place them in the treatment sequence?	Eric Small	15 min
18.15 – 18.30	Discussion		
18.30 – 18.50	Vote consensus questions		